Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Unigene To Manufacture Novartis' Osteoporosis Peptide | Contract Pharma

What are you searching for?

Sign in
Breaking News

Unigene To Manufacture Novartis’ Osteoporosis Peptide

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Unigene Laboratories, Inc. will receive a $2.5 million payment to supply Novartis with specified quantities of a bulk peptide necessary to support Novartis’ development program for an osteoporosis treatment. Unigene will use its manufacturing technology to develop an FDA-compliant process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary. Some of this material may be used in clinical studies.

In 2004, Novartis exclusively licensed Unigene’s technology to manufacture another peptide, calcitonin, and now runs the scaled-up process at its manufacturing facility in Kundl, Austria.

“We are very pleased to expand our relationship with Novartis,” commented Dr. Ronald S. Levy, executive vice president of Unigene. “They have a strong commitment to peptide therapeutics as well as to osteoporosis products. Our calcitonin collaboration has been extremely successful, and we hope to have additional opportunities to work with them.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters